April 3, 2019
Sandoz resubmitting BLA for chemotherapy drug to the FDA
Sandoz is resubmitting its Biologics License Application for a proposed biosimilar pegfilgrastim to the US FDA
Pharmaceuticals, Biotechnology and Life Sciences
Tag: cancer
March 22, 2019
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST.…
March 20, 2019
First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute
STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient…
February 11, 2019
Immunicium to treat cancer patients with its lead in-development-product, ILIAD
Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.
January 15, 2019
China’s Innovent Biologics preparing to advance IBI188 into subsequent clinical trials in a variety of cancers
Innovent Biologics has dosed the first patient in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.
January 11, 2019
ValiRX finds support for future studies of VAL401 as a cancer treatment
ValiRx’s published study of VAL401, a single dose in an open-label trial of late-stage cancer patients, provide support for future studies of VAL401 as a cancer treatment, as the Cmaxdemonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.
January 7, 2019
4D pharma to test its diverse cancer settings Live Biotherapeutic oncology pipeline with University of Texas MD Anderson Cancer Center
4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release
December 21, 2018
ObsEva in third phase testing looks at long term administration of linzagolix
ObsEva is evaluating long term administration of linzagolix in two dosing regimens with recruited patients for third phase of testing oral gonadotropin releasing hormone (GnRH) receptor antagonist Linzagolix.
December 10, 2018
ValiRx’s leading anti-cancer therapeutic reduces PSA in phase 2 clinical trial
ValiRx journey of bringing closer to market its leading anti-cancer therapeutic VAL201 for patients with hormone-sensitive and hormone-resistant prostate cancer, took a…
December 3, 2018
Mundipharma China to sell Swiss Helsinn’s first cancer supportive care in China
Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the…